Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines: Discussion

Plastic and Reconstructive Surgery

Volumn 112, Issue 5 SUPPL., 2003, Pages

  Fagien, Steven ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

AGING; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; ESTHETICS; FACE; FLU LIKE SYNDROME; HUMAN; MORBIDITY; NOTE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; WRINKLE;

EID: 33750874432     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000082191.75620.7F     Document Type: Note

References (5)

1. Kowalski, J. W., Sengelmann, R. D., Waldorf, H., Fagien, S., Fields, N., and Mackowiak, J. Development, validity, and reliability of the facial lines self-confidence and perception (FSP) questionnaire. Presented at the Ninth Annual Meeting of the International Society for Quality of Life Research, Orlando, Fla., October 30, 2002.
2. Allergan Corporation. Botox cosmetic prescribing information (Package insert). Irvine, Calif.: Allergan. Available at: http://wvw.allergan.com/ download/BOTOX_Cosmetic_PI.pdf.
3. Irena and Michael Medavoy v Allergan and Arnold W. Klein, M.D. (No. SC075614). State of California, January 2003.
4. Fagien, S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in facial aesthetic surgery. Plast. Reconstr. Surg. 103: 701, 1999.
5. Becker, D. S. Muscle recruitment as a potential side effect of botulinum toxin therapy. Cosmetic Dermatol. 15: 35, 2002.